Inhibrx Biosciences Hits Day Low of $91.84 Amid Price Pressure

Inhibrx Biosciences, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock declining by 10.44%. The stock reached an intraday low of USD 91.84, reflecting a challenging trading environment. Over the past week, Inhibrx has seen a decrease of 4.68%, contrasting with a modest gain of 1.23% in the S&P 500. Despite a strong annual performance of 343.33%, the company has reported negative results for March 2026, following three consecutive quarters of positive outcomes. This downturn has raised concerns about its long-term growth potential, as evidenced by a net sales decline of 16% annually over the past five years. Financial metrics indicate a weak long-term fundamental strength, with a return on capital employed (ROCE) at a notably low -354.69%. Additionally, promoter confidence appears to be waning, as stakeholders have reduced their holdings by 0.81% in the last quarter. Inhibrx's current market capitalization stands at USD 853 million, and it remains net-debt free, although its operational losses continue to be a point of concern.